Evidence map›Paper›PMID 31294086›Full record

ReviewEndocrinology, diabetes & metabolism2019

Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease.

Sebastian Niezen, Humberto Diaz Del Castillo, Lumen A Mendez Castaner, Alessia Fornoni

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Endocrinology, diabetes & metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Sebastian NiezenSchool of Medicine Anahuac University Mexico City Mexico.
Humberto Diaz Del CastilloSchool of Medicine Universidad Autónoma de Guadalajara Guadalajara Mexico.
Lumen A Mendez CastanerKatz Family Division of Nephrology and Hypertension University of Miami Miami Florida.ORCID https://orcid.org/0000-0002-3383-1359
Alessia FornoniKatz Family Division of Nephrology and Hypertension University of Miami Miami Florida.
University of Miami · USUniversidad Anáhuac · MXUniversidad Autónoma de Guadalajara · MX

Funding

Training Program in Clinical & Translationa Research in Human Glomerular DiseaseU54DK083912 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HOLZMAN, LAWRENCE B. · 2009 to 2023
$20.3M
Miami Clinical and Translational Science InstituteUL1TR000460 · NCATS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SACCO, RALPH L. · 2012 to 2016
$16.9M
Crosstalk Between Lipid Droplets and Other Organelles in PodocytesR01DK104753 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI FORNONI, ALESSIA · 2015 to 2025
$5.9M
Primary Outcomes in Glomerulonephritis Study (PROGRESS)UM1DK100846 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI HOLZMAN, LAWRENCE B. · 2013 to 2018
$5.8M
1/13 ApoL1 Genotypes in Kidney Donors and Long-Term Outcomes in Kidney Transplant Recipients Clinical CenterU01DK116101 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI ALESSIA FORNONI, Mariella Cecilia Ortigosa-goggins · 2017 to 2026
$2.4M
(PQ12) Targeting SMPDL3b to Prevent Radiation-Induced NephrotoxicityR01CA227493 · NCI · UNIVERSITY OF ROCHESTER · PI MARPLES, BRIAN · 2018 to 2022
$2.0M
SMPDL3b and podocyte insulin signaling in DKDR01DK117599 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI FORNONI, ALESSIA · 2018 to 2021
$1.4M
NCATS NIH HHS UL1 TR000460NCI NIH HHS R01 CA227493NIDDK NIH HHS R01 DK104753NIDDK NIH HHS R01 DK117599NIDDK NIH HHS U01 DK116101NIDDK NIH HHS U54 DK083912NIDDK NIH HHS UM1 DK100846
6 · The paper itself

Abstract

Diabetic kidney disease (DKD) is the major contributor to the mortality and the financial burden of diabetes, accounting for approximately 50% of the cases of end-stage renal disease (ESRD) in the developed world. Several studies have already demonstrated that achieving blood pressure targets in DKD with agents blocking the renin-angiotensin system confer superior renoprotection when compared to other agents. However, the effects on renal outcomes of antihyperglycaemic agents in these patients have not been reported or studied broadly until recent years. The intent of this article is to review the available data on safety, efficacy, impact on renal outcomes and pathophysiology implications of the most utilized antihyperglycaemic agents in DKD/ESRD.

Indexed as

antihyperglycaemic agentchronic kidney diseasediabetic kidney diseaseefficacysafety

Identifiers

PMID31294086
PMCPMC6613230
OpenAlexW2946768042

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.